Multiple Myeloma Industry Forecast to Hit $38.16 Billion by 2029 With a Strong 8% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Multiple Myeloma Market Size During 2025–2029?

The multiple myeloma market has experienced robust growth in recent years. It is projected to expand from $26.07 billion in 2024 to $28.05 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.6%. This historical growth can be attributed to several factors including enhancements in diagnostics, the introduction of stem cell transplantation, improved access to high-quality medical care, the adoption of precision medicine approaches, and the development of patient-centric care models.

The multiple myeloma market is projected to experience robust expansion in the coming years, with its size anticipated to reach $38.16 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.0%. This growth during the forecast period can be attributed to factors such as health technology integration, the increasing adoption of telemedicine services, the emergence of personalized vaccine therapies, and the deployment of digital health platforms for patient education. Key trends expected in the upcoming period include advancements in targeted therapies, novel drug development, progress in immunotherapy, the evolution of novel biomarkers, and the integration of artificial intelligence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12163&type=smp

What Are The Key Drivers Of Growth In The Multiple Myeloma Market?

The multiple myeloma market is anticipated to expand due to the rising occurrence of multiple myeloma. This condition, multiple myeloma, is characterized as a form of cancer originating in plasma cells, which are a type of white blood cell. Factors contributing to the rise in multiple myeloma cases include age, genetic predispositions, obesity, exposure to radiation, and various other health conditions. Treatments available for multiple myeloma aim to decelerate its progression and alleviate its symptoms. An illustration of this trend is provided by the American Cancer Society, a voluntary health organization situated in the US, which reported an increase in new multiple myeloma cases from 34,470 in 2022 to 35,730 in 2023. Consequently, the growing frequency of multiple myeloma is serving as a catalyst for the expansion of the multiple myeloma market.

Which Key Segments Fueling The Multiple Myeloma Market?

The multiple myelomamarket covered in this report is segmented –

1) By Treatment: Medications; Radiation Therapy; Stem Cell Transplant; Other Treatments

2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Urine Tests; Imaging Tests

3) By Disease Type: Active Multiple Myeloma; Smoldering Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Channels

Subsegments:

1) By Medications: Immunomodulatory Drugs (IMiDs); Proteasome Inhibitors; Monoclonal Antibodies; Corticosteroids; Chemotherapy Agents

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioisotope Therapy

3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT); Allogeneic Stem Cell Transplant

4) By Other Treatments: Supportive Care; Clinical Trials And Experimental Therapies

What Key Innovation Trends Are Fueling Advancements In The Multiple Myeloma Market?

Product innovation represents a significant trend gaining momentum in the multiple myeloma market. Major companies operating within the multiple myeloma market are developing advanced products to sustain their position. For instance, in October 2022, the US Food and Drug Administration (FDA) granted approval for TECVAYLI (teclistamab-cqyv), the first bispecific T-cell engager antibody, to Janssen Pharmaceutical Companies of Johnson & Johnson, a Belgium-based pharmaceutical company. This drug is indicated for treating adult patients with multiple myeloma who have undergone at least four prior lines of therapy, including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies against CD38. It functions by targeting the B-cell maturation antigen (BCMA), expressed on the surface of some healthy B-lineage cells, and the CD3 receptor, expressed on the surface of T-cells and multiple myeloma cells.

Who Are The Key Multinational Companies Dominating The Multiple Myeloma Market?

Major companies operating in the multiple myeloma market include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Mylan N.V., Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics AG, Karyopharm Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Allogene Therapeutics Inc., C4 Therapeutics Inc., Adaptimmune Therapeutics plc, Precision Biosciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Which Region Is Projected To Lead The Multiple Myeloma Market During The Forecast Period?

North America was the largest region in the multiple myeloma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Multiple Myeloma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12163&type=smp

Browse Through More Reports Similar to the Global Multiple Myeloma Market 2025, By The Business Research Company

Amusement Parks Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/amusement-parks-global-market-report

Spa Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/spa-global-market-report

Low Speed Electric Vehicle Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/low-speed-electric-vehicle-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795